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Introduction
The search for specific breast cancer risk factors has
been stimulated by the large differences in rates of the
disease observed among countries [1], and by changes
in rates in migrating populations [2,3] and within
countries over time [4,5].
Several breast cancer risk factors have been known for
many years [6,7]. Increasing age is one of the strongest
risk factors. Having a family history of breast cancer
increases a woman’s own risk; an earlier age at diagnosis
and greater number of affected relatives augments her
risk. Early age at menarche, late age at menopause,
nulliparity and late age at first birth modestly, but
consistently, increase risk [8]. Breastfeeding, particularly
for long durations, is associated with lower risk [9]. Both
height and postmenopausal body mass index are
positively associated with disease, while premenopausal
obesity is inversely associated, at least in Western
populations [10]. A personal history of benign breast
disease, particularly with atypia [11,12], and having dense
breasts on a mammogram [13] are both associated with
substantial increases in breast cancer. Alcohol intake, the
only dietary factor currently well established, also is
associated with an increase in risk, although the
relationship is modest [14].
Over the past 10–15 years substantial additional progress
has been made in delineating risk factors for breast
cancer. Contributions of particular note include the
discovery of several gene mutations (e.g. in BRCA1,
BRCA2 and PTEN genes) and quantification of the risk
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Abstract
While the association of a number of risk factors, such as family history and reproductive patterns,
with breast cancer has been well established for many years, work in the past 10–15 years also has
added substantially to our understanding of disease etiology. Contributions of particular note include
the delineation of the role of endogenous and exogenous estrogens to breast cancer risk, and the
discovery and quantification of risk associated with several gene mutations (e.g. BRCA1). Although it
is difficult to integrate all epidemiologic data into a single biologic model, it is clear that several
important components or pathways exist. Early life events probably determine both the number of
susceptible breast cells at risk and whether mutations occur in these cells. High endogenous
estrogens are well established as an important cause of breast cancer, and many known risk factors
appear to operate through this pathway. Estrogens (and probably other growth factors) appear to
accelerate the development of breast cancer at many points along the progression from early
mutation to tumor metastasis, and appear to be influential at many points in a woman’s life. These
data now provide a basis for a number of strategies that can reduce risk of breast cancer, although
some strategies represent complex decision-making. Together, the modification of nutritional and
lifestyle risk factors and the judicious use of chemopreventive agents could have a major impact on
breast cancer incidence. Further research is needed in many areas, but a few specific arenas are
given particular mention.
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associated with them [15,16]. Although long proposed
[17], both observational studies and randomized trials
have confirmed and quantified the important role of
estrogens, both exogenous and endogenous, in breast
cancer etiology. Specifically, circulating estrogen levels in
postmenopausal women are positively associated with risk
[18], and the use of therapies, such as tamoxifen, that
block the binding of estrogen to the estrogen receptor at
the breast decrease the risk of disease [19–21]. The use
of postmenopausal estrogens, particularly when combined
with a progestin, also increases the disease risk in women
[22–25]. Furthermore, risk increases with duration of use
of postmenopausal hormones. Although factors have long
been suspected to influence breast carcinogenesis during
early life, the hypothesis that even in utero exposures
influence risk is much more recent [26] and has been
increasingly supported [27,28]. However, many
methodologic challenges exist in confirming these ideas.
Finally, progress has been steady in further delineating the
probable protective role of physical activity [29] and in
evaluating more recent dietary hypotheses such as folate
intake [30].
Known and suspected risk factors are presented in
Table 1, and approximate strengths of association are
provided for specific comparisons. Note, however, that
these comparisons are somewhat arbitrary because many
of these risk factors are continuous variables and the
relative risks will depend on the magnitude of the
contrasts chosen for comparison (e.g. a 5-year difference
versus a 10-year difference in age at menopause). While
many of these risk factors are established with a high
degree of certainty, some, such as high prolactin levels
and low physical activity, will require further research for
confirmation.
A biologic model of breast cancer etiology
Mechanisms linking risk factors to the development of
breast cancer are known with varying levels of certainty.
Although it is difficult to integrate all epidemiologic data
into a single biologic model, it is clear that several
important pathways or components exist. Of critical
importance in breast cancer etiology is the timing of
exposure in a woman’s life. For example, exposures that
occur early in life can have an influence on risk that is quite
different from that resulting from the same exposure
occurring years later (e.g. radiation exposure [31,32]). In
addition, a single exposure can have opposing influences
on risk at different times in life (e.g. parity [33]).
Early life events probably determine both the number of
susceptible breast stem cells at risk and whether mutations
occur in these cells. The relatively consistent positive
association of risk with birthweight and the well-confirmed
association with height (a marker of childhood nutritional
status and associated growth factors) strongly suggest an
influence of early events, perhaps even those occurring in
utero, to subsequent risk. Mammographic breast density
may, at least in part, be a marker of the number of at-risk
cells in the breast. Mutations in these cells can be inherited
(e.g. mutations in BRCA1 or p53) or acquired, such as by
exposure to ionizing radiation. Oxidative damage from
endogenous metabolism is hypothesized to contribute to
DNA damage [34] but the importance of this mechanism to
breast carcinogenesis is not clear. To the extent that
oxidative damage is important, dietary antioxidants might
reduce risk and their role may be particularly important
Table 1
Epidemiology of breast cancer: abbreviated risk factor
summary
Direction of 
Risk factor effecta
Well-confirmed risk factors
Family history in first-degree relative or genetic  ↑↑
predisposition (e.g. BRCA1)
Height ↑
Benign breast disease ↑↑
Mammographically dense breasts ↑↑
Parity ↓
Age at first birth > 30 years versus at < 20 years ↑↑
Lactation (longer durations) ↓
Menopause at > 54 years versus at < 45 years ↑↑
High endogenous estrogen levels ↑↑
Postmenopausal hormone use ↑
Ionizing radiation exposure in childhood ↑↑
Menarche at < 12 years versus at > 14 years ↑
High body mass index (postmenopausal) ↑
High body mass index (premenopausal)b ↓
Alcohol use (~ 1 or more drinks/day) ↑
Probable relationship exists, based on substantial data
Current oral contraceptive use ↑
Physical activity ↓
Limited study to date
High prolactin levels ↑↑
High premenopausal insulin-like growth factor I levels ↑↑
In utero exposures ↑
Nonsteroidal anti-inflammatory drug use ↓
a Arrows indicate approximate magnitude of the relationship: ↑, slight
to moderate increase in risk; ↑↑, moderate to large increase in risk; ↓,
slight to moderate decrease in risk; ↓↓, moderate to large decrease in
risk.
b In Western countries — data are less consistent in other lower risk
populations.215
early in life. Low availability of folate (and its cofactors such
as vitamin B6 and B12), particularly in conjunction with
high alcohol intake, can lead to abnormal DNA synthesis
and repair and aberrant DNA methylation [35], and hence
may play a role in breast carcinogenesis.
Pregnancy has a particularly complex influence on
subsequent breast cancer risk. For about a decade after
the pregnancy, risk is increased, probably due to the
hormonal stimulation of already initiated breast epithelial
cells [33]. In contrast, risk is reduced over the long term,
possibly by rendering the breast substantially less
susceptible to somatic mutations [36]. An earlier age at
first pregnancy also is associated with a reduction in risk
as it may shorten the time (from menarche to first birth)
when the breast is particularly susceptible to mutations.
As already noted, high endogenous estrogen levels in
postmenopausal women are now well established as an
important cause of breast cancer, and many known risk
factors appear to operate through this pathway. The
additional contribution of cyclical estrogen exposure (as
opposed to continuously high levels) is less clear, and
much evidence indicates that progestins add to breast
cancer risk [22–25]. Factors that increase lifetime
exposure to estrogens and progesterone include early age
at menarche, regular ovulation, and late age at
menopause. Breastfeeding and being overweight during
the woman’s young adult life decrease the ovulatory
frequency, and this probably accounts, at least in part, for
their protective effects. In addition to its role in folate
absorption and metabolism, alcohol intake increases
endogenous estrogen levels that may contribute to the
observed increase in risk among regular drinkers [37,38].
The modest increase in risk of breast cancer among
current or recent users of oral contraceptives is probably
due to their estrogenic (and probably progestational)
effects [39]. In postmenopausal women, both adiposity
and the use of postmenopausal hormones are primary
determinants of estrogen exposure, and also increase
breast cancer risk. Increases in physical activity can delay
the onset of menarche and can also reduce the risk of
breast cancer by helping to control weight gain and by
modifying bioavailable hormone levels. Other growth
factors in addition to estrogens, particularly insulin-like
growth factor I [40] and prolactin [41], are also likely to
contribute to breast cancer risk, although these
relationships are less firmly established.
Importantly, estrogens (and probably other growth
factors), by their mitotic effects on breast cells, appear to
accelerate the development of breast cancer at many
points along the progression from early mutation to tumor
metastasis. By increasing cell proliferation, estrogens may
also increase the probability that DNA damage is not
repaired, resulting in mutations [42]. In addition, estrogens
may be directly genotoxic, through their reactive
metabolites [43], although evidence for this mechanism is
more limited. Although exposure to high estrogen levels
early in life increases risk decades later, reduction in levels
late in life can reduce risk rather quickly, whether this
exposure is via oophorectomy, cessation of postmeno-
pausal hormones, or the administration of anti-estrogens.
This broad outline of breast carcinogenesis, generally
similar to that previously described by other scientists
(see, for example [44,45]), seems unlikely to change sub-
stantially in the future, although further research will
certainly fill in details of the aforementioned relationships
and will identify other contributing factors. For example,
we will probably identify genetic polymorphisms that
contribute to variation in endogenous levels of, or
responsiveness to, estrogens and other growth factors.
Also, other molecular mechanisms such as DNA repair
and apoptosis are thought to be important in
carcinogenesis in general, but the extent to which
exogenous factors influence these processes in the
context of human breast cancer is not yet known.
Current opportunities for primary prevention
of breast cancer
A number of breast cancer risk factors are now well
established and a subset of them, such as reproductive
factors and postmenopausal obesity, account for a large
part of the high breast cancer rates seen in affluent
Western populations [46–48]. However, this knowledge
does not necessarily translate easily into strategies for
breast cancer prevention. Several risk factors (such as
age at menarche or family history), while well established,
are difficult or impossible to modify; some (such as alcohol
intake) are well established but carry complex risks and
benefits; and other risk factors (such as high vegetable
and fruit consumption) are not as proven, but have other
important benefits that justify the strategy, with reduction
in breast cancer being a possible additional benefit.
Known risk factors for breast cancer are also modest in
magnitude, with relative risks generally in the range of
1.3–1.8 for attainable changes. Although these
associations are not strong, they remain important. When
considering primary prevention, even modest changes at
the individual level can produce substantial changes in the
population rates of disease [49].
Encouraging physical activity early in life is desirable and,
through a modest delay in age at menarche [50,51],
should contribute to some reduction in breast cancer risk.
Avoiding weight gain during adult life plays an important
role in reducing the risk of postmenopausal breast cancer,
as well as many other chronic diseases. Individual women
can minimize weight gain by exercising regularly and
moderately restraining caloric intake. It is important to note
that while some strategies for breast cancer prevention,
such as weight control, can be implemented by individuals
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themselves, the health system, governments, and society
as a whole also can, and should, play a role. For example,
the incorporation of increased physical activity into daily
life would be greatly facilitated for both children and adults
if far greater emphasis was placed on daily physical
activity in schools and the provision of safe and easily
accessible exercise facilities and environments (e.g. cycle
paths) in the community and at the workplace.
Alcohol consumption has a complex mix of desirable and
adverse health effects, one of which is an increase in
breast cancer. Individuals should make decisions
considering all the risks and benefits, but for a middle-
aged woman who drinks alcohol on a daily basis, reducing
intake is one behavioral change that is likely to reduce the
risk of breast cancer. No other specific aspects of diet are
well established to influence breast cancer risk. However,
several dietary habits, such as high consumption of fruits
and vegetables and the replacement of saturated fats and
trans fats with monounsaturated fat, are important for
reducing risk of heart disease [52], and could also prove
to modestly decrease the risk of breast cancer.
Postmenopausal hormone use involves a complex trade-
off of benefits and risks. From the standpoint of breast
cancer, the best strategy would be to use estrogens for
only a few years for menopausal symptoms, if at all. In
particular, the combined use of estrogen plus progestin,
associated with a greater risk increase, should be avoided
or minimized. The range of other pharmacologic options to
treat osteoporosis has been rapidly expanding, several of
which (e.g. raloxifene [20,53]) may simultaneously reduce
the risk of breast cancer. Few, if any, similarly effective
options exist for alleviating menopausal symptoms,
however, and research is needed to provide alternatives to
currently available hormone therapy.
With the demonstration that tamoxifen, and probably other
selective estrogen receptor modulators (SERMs), can be
effective in the primary prevention of breast cancer
[19,20], chemoprevention has become an option for
women at elevated risk. A number of other pharmacologic
agents, such as aromatase inhibitors [54], are being
evaluated at present and are likely to increase the
alternatives in the relatively near future. Identifying who
would most benefit from these agents, all of which to date
have potential adverse consequences associated with
their use, remains an important issue.
In summary, available evidence provides a basis for a
number of strategies that can reduce risk of breast cancer,
although some of these represent complex decision-
making. Together, the modification of nutritional and
lifestyle risk factors and the judicious use of
chemopreventive agents should have a major impact on
incidence of this important disease.
Future research in breast cancer etiology
Further research is needed in many areas, but a few
specific arenas deserve particular note. During most of the
past several decades, epidemiologists have largely
focused on adulthood exposures and risk of breast
cancer. With increasing recognition that early life
exposure also plays a role, a continued and expanded
emphasis needs to be placed on the prenatal period
through the premenopausal years. A number of innovative
studies have been conducted [55,56]; more are needed,
however, as is a greater commitment to the conduct of
very long-term prospective studies that start early in life.
An emphasis on the validation of early exposure
assessments is also needed.
The continued incorporation of advances in genetics and
molecular biology into epidemiologic studies is a priority.
The evaluation of gene polymorphisms and haplotypes,
particularly in conjunction with environmental and other
lifestyle exposures, will further our understanding of the
causal nature of a number of observed associations, as
well as our understanding of breast cancer etiology more
generally. In addition, while most early studies considered
breast cancers as a single disease entity, several studies
[57,58] have shown that risk factors vary by estrogen
receptor status and progesterone receptor status of the
tumor. Further molecular characterization of breast tumors
will again provide substantial insight into etiology and a
greater understanding of certain exposure/breast cancer
relationships (e.g. an exposure that is weakly or
inconsistently associated with breast cancer risk overall
may be strongly associated with a particular tumor
subtype). Many of these efforts, however, will require very
large studies, or the pooling of data across studies.
The availability of effective chemopreventive agents, such
as SERMs, has raised many questions about the optimal
criteria for use of these drugs; that is, how to determine
which women are at high risk and hence the best
candidates for their use. Until recently, risk has been
primarily based on an evaluation of family and reproductive
history and a history of benign breast disease [59]. New
information on risk based on genotype, mammographic
density [13], and serum hormone levels [18,53] should
now allow a much more powerful prediction of risk for an
individual woman — development and validation of these
models is critical.
A number of other possible candidates for
(chemo)prevention exist. For example, a preventive role for
aspirin and other nonsteroidal anti-inflammatory medica-
tions has been suggested [60]. Further assessment of
these associations with breast cancer risk, as well as
intermediates such as mammographic density, may provide
further avenues for prevention. The role of diet, such as
folate and vitamin D intake, needs further evaluation. Other
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areas of emphasis should include the identification of
lifestyle factors that can improve, and biologic markers that
can predict, breast cancer prognosis.
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